Acute Myeloid Leukemia With FLT3/ITD Mutation Clinical Trial
Official title:
A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia
This study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction therapy. Those patients entering a complete remission or a complete remission with incomplete blood count recovery will be allowed to proceed to consolidation therapy with vyxeos and gilteritinib. Those patients who do not proceed to an allogeneic stem cell transplant for any reason are able to enter the maintenance phase of this trial using daily gilteritinib
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05596981 -
The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT
|
||
| Recruiting |
NCT05596968 -
The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
|
||
| Terminated |
NCT01028716 -
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
| Not yet recruiting |
NCT05876832 -
A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)
|
Phase 3 | |
| Completed |
NCT03735875 -
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Completed |
NCT01578109 -
Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia
|
Phase 1 | |
| Completed |
NCT04788420 -
Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML
|
||
| Recruiting |
NCT06222580 -
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
|
Phase 1 | |
| Active, not recruiting |
NCT03333486 -
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
|
Phase 2 | |
| Terminated |
NCT02634827 -
Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation
|
Phase 2 | |
| Completed |
NCT01760655 -
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
|
Phase 2 | |
| Recruiting |
NCT04174612 -
AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance
|
Phase 3 | |
| Completed |
NCT01253070 -
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
|
Phase 2 |